

Fluidx Medical Closes Financing to Advance Next-Generation Embolic Platform

Investment will support commercialization of GPX and ULTRA Embolic Devices and development of IMPASS neurovascular platform.

SALT LAKE CITY, UT, UNITED STATES, August 6, 2026 /EINPresswire.com/ -- [Fluidx](#) Medical

“

This financing is an important milestone for Fluidx as we continue executing on our mission to redefine embolization with technologies that are simple to use and highly controllable.”

Libble Ginster, CEO of Fluidx Medical Technology, Inc.

Technology, Inc., a developer of innovative embolic technologies, today announced the successful closing of financing to fund development and growth. The financing follows significant momentum across Fluidx's product portfolio, including completion of the [GPX](#) IDE clinical trial and continued advancement of [ULTRA](#). The additional capital will also accelerate development of IMPASS, Fluidx's next-generation neurovascular embolic technology, building on encouraging preclinical results recently presented at the Society of NeuroInterventional Surgery (SNIS) Annual Meeting.

"This financing is an important milestone for Fluidx as we

continue executing on our mission to redefine embolization with technologies that are simple to use and highly controllable," said Libble Ginster, Chief Executive Officer of Fluidx Medical. "The funding strengthens our ability to bring GPX and ULTRA to market while advancing IMPASS through key clinical milestones."

The investment will be used to expand manufacturing and commercial readiness activities for GPX and ULTRA Embolic Devices, and accelerate clinical activities of IMPASS as Fluidx continues to build a broad portfolio of embolic solutions for peripheral and neurovascular interventions.

About Fluidx Medical Technology:

Fluidx Medical Technology, Inc. is a Salt Lake City, Utah based company focused on developing a new, innovative category of easy to use, controllable embolic gels that can treat the widest range of clinical conditions, effectively occluding the smallest vessels up to the largest vessels. The current pipeline includes the GPX, ULTRA, and IMPASS embolic technologies with applications across peripheral vascular, interventional oncology, and neurovascular embolization. Unlike other embolic devices, the Fluidx Medical Technology portfolio does not use toxic dimethyl sulfoxide (DSMO) or other precursors, glue catheters into the body, require special delivery

systems, or need special mixers and preparation stations.

GPX, ULTRA, and IMPASS Embolic Devices are under development, described and shown for research, educational, and engineering use only, and do not have marketing clearance or approval in any market at this time.

Russell Bjorklund

Fluidx Medical Technology

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/932045330>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.